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A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets 
Prepared by Extemporaneous Compounding 
Abstract 
Dehydroepiandrosterone supplementation is used to treat a variety of conditions. Rapid-dissolving tablets 
are a relatively novel choice for compounded dehydroepiandrosterone dosage forms. While rapid-
dissolving tablets offer ease of administration, there are uncertainties about the physical and chemical 
stability of the drug and dosage form during preparation and over long-term storage. This study was 
designed to evaluate the stability of dehydroepiandrosterone rapid-dissolving tablets just after 
preparation and over six months of storage. The Professional Compounding Centers of America rapid-
dissolving tablet mold and base formula were used to prepare 10-mg strength dehydroepiandrosterone 
rapid-dissolving tablets. The formulation was heated at 100°C to 110°C for 30 minutes, released from the 
mold, and cooled at room temperature for 30 minutes. The resulting rapid-dissolving tablets were 
individually packaged in amber blister packs and stored in a stability chamber maintained at 25°C and 
60% relative humidity. The stability samples were pulled at pre-determined time points for evaluation, 
which included visual inspection, tablet weight check, United States Pharmacopeia disintegration test, 
and stability-indicating high-performance liquid chromatography. The freshly prepared 
dehydroepiandrosterone rapiddissolving tablets exhibited satisfactory chemical and physical stability. 
Time 0 samples disintegrated within 40 seconds in water kept at 37°C. The highperformance liquid 
chromatographic results confirmed that the initial potency was 101.9% of label claim and that there was 
no chemical degradation from the heating procedure. Over six months of storage, there were no 
significant changes in visual appearance, physical integrity, or disintegration time for any of the stability 
samples. The high-performance liquid chromatographic results also indicated that 
dehydroepiandrosterone rapid-dissolving tablets retained >95% label claim with no detectable 
degradation products. The dehydroepiandrosterone rapid-dissolving tablets investigated in this pilot study 
were physically and chemically stable during preparation and over six months of storage at 25°C and 60% 
relative humidity. 
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A Pilot Stability Study of Dehydroepiandrosterone 
Rapid-dissolving Tablets Prepared by 
Extemporaneous Compounding 
ABSTRACT
Dehydroepiandrosterone supplementation is used to treat a variety of 
conditions. Rapid-dissolving tablets are a relatively novel choice for 
compounded dehydroepiandrosterone dosage forms. While rapid-dissolving 
tablets offer ease of administration, there are uncertainties about the physical 
and chemical stability of the drug and dosage form during preparation and 
over long-term storage. This study was designed to evaluate the stability of 
dehydroepiandrosterone rapid-dissolving tablets just after preparation and 
over six months of storage. The Professional Compounding Centers of America 
rapid-dissolving tablet mold and base formula were used to prepare 10-mg 
strength dehydroepiandrosterone rapid-dissolving tablets. The formulation 
was heated at 100°C to 110°C for 30 minutes, released from the mold, and 
cooled at room temperature for 30 minutes. The resulting rapid-dissolving 
tablets were individually packaged in amber blister packs and stored in a 
stability chamber maintained at 25°C and 60% relative humidity. The stability 
samples were pulled at pre-determined time points for evaluation, which 
included visual inspection, tablet weight check, United States Pharmacopeia 
disintegration test, and stability-indicating high-performance liquid 
chromatography. The freshly prepared dehydroepiandrosterone rapid-
dissolving tablets exhibited satisfactory chemical and physical stability. Time 0 
samples disintegrated within 40 seconds in water kept at 37°C. The high-
performance liquid chromatographic results confirmed that the initial potency 
was 101.9% of label claim and that there was no chemical degradation from the 
heating procedure. Over six months of storage, there were no significant 
changes in visual appearance, physical integrity, or disintegration time for any 
of the stability samples. The high-performance liquid chromatographic results 
also indicated that dehydroepiandrosterone rapid-dissolving tablets retained 
>95% label claim with no detectable degradation products.  The 
dehydroepiandrosterone rapid-dissolving tablets investigated in this pilot 
study were physically and chemically stable during preparation and over six 
months of storage at 25°C and 60% relative humidity.
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INTRODUCTION
     Dehydroepiandrosterone (DHEA) is an 
important steroid produced primarily by 
the adrenal gland. Its chemical structure 
is shown in Figure 1. DHEA and its sulfate 
conjugate (DHEAS) are the most abundant 
circulating steroid hormones in the body 
and serve as a reservoir for the biosynthe-
sis of other more potent sex hormones, 
such as testosterone and estradiol.1-3                                            
F I G U R E  1 .  CHEMICAL STRUCTURE OF 
DEHYDROEPIANDROSTERONE.
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Recent studies reveal that DHEA is a 
neurosteroid with important functions in 
the mammalian brains.4-6 Levels of DHEA 
and DHEAS peak in early adulthood and 
decline steadily afterwards at a rate of 
about 10% per decade.2 Supplementation 
of DHEA has been proposed to treat a wide 
variety of conditions, such as sexual dys-
function, decline in cognitive functions, 
osteoporosis, and infertility.2,7-9 However, 
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many claims are still 
awaiting evidence 
from adequately 
powered, long-term 
clinical trials. DHEA 
is regulated as a 
dietary supplement 
in the U.S., and com-
mercial products 
are available as oral 
capsules/tablets, 
intra-oral spray, and 
transdermal creams/
gels. However, qual-
ity issues of these 
commercial products 
have been revealed 
by independent 
laboratory analysis, 
and patients are rec-
ommended to obtain 
DHEA supplements 
from compounding 
pharmacies.2 
     With the recent 
introduction of 
special molds and base formulas, rapid-dissolving tab-
lets (RDTs) are gaining popularity among compounded 
dosage forms. DHEA in RDT dosage forms can offer ease 
of administration for general patients and serve as an ef-
fective option for patients who cannot swallow tablets or 
have absorption issues (e.g., due to gastric bypass). How-
ever, the new excipients, compounding methods, and 
physical properties of RDTs are significantly different 
from those of the conventional solid dosage forms, such 
as compressed tablets or hard-gelatin capsules. There 
are new uncertainties about the drug and dosage form 
stability during preparation and over long-term storage. 
     This pilot study was designed to evaluate the chemical and 
physical stability of a representative DHEA RDT formulation im-
mediately after preparation and over six months of storage. Such 
information will aid the compounding pharmacists in establishing 
proper storage conditions and beyond-use dates of similar DHEA 
RDT preparations.
MATERIALS AND METHODS
MATERIALS
     All ingredients for the RDTs were purchased from Professional 
Compounding Centers of America (PCCA) (Houston, Texas), and 
they include DHEA micronized powder 
(Cat 55-2960), RDT powder base (Cat 
30-3269), steviol glycosides (Cat 30-4539), 
acesulfame potassium (Cat 30-4398), 
and peppermint oil flavor (Cat 30-3462). 
The 96-cavity RDT mold (Cat 35-3791) 
and the blister packs with adhesive label 
backing (Cat 35-2512 and Cat 35-2671) 
were also obtained from PCCA. For 
high-performance liquid chromatogra-
phy (HPLC) analysis, a reference stan-
dard of DHEA bulk drug substance (Lot 
A0329093; Cat AC154980100), 0.45-µm 
F I G U R E  2 .  APPEARANCE OF RAPID-DISSOLVING TABLETS AFTER THEY ARE RELEASED FROM THE MOLD.
DHEA = dehydroepiandrosterone; RDT = rapid-dissolving tablet
T A B L E  1 .  DEHYDROEPIANDROSTERONE RAPID-DISSOLVING TABLET FORMULA.
  A M O U N T  P E R  B A T C H
I N G R E D I E N T  A M O U N T  P E R  R D T  ( 9 6  R D T S )
DHEA micronized powder 10 mg 0.960 g
RDT base powder 625 mg 59.992 g
Steviol glycosides 3 mg 0.288 g
Acesulfame potassium 4 mg 0.384 g
Peppermint oil flavor ~0.04 drop 4 drops
Total (excluding flavor) 642 mg 61.6 g
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PVDF syringe filters, and acetonitrile (Cat A998-4) were pur-
chased from Fisher Scientific (Hanover Park, Illinois); Type I 
purified water was obtained using a Milli-Q system from Millipore 
(Billerica, Massachusetts). 
RAPID-DISSOLVING TABLETS FORMULA AND 
COMPOUNDING
     The formula of 10-mg DHEA RDTs is listed in Table 1. In ad-
dition to the drug and RDT base, small amounts of two artificial 
sweeteners and a flavor were included. For each batch prepara-
tion, the ingredients were mixed thoroughly and press-filled into 
the cavities of a RDT mold. The filled RDT mold was heated in a 
convection oven at 100°C to 110°C for 30 minutes. The resulting 
RDTs were cooled to room temperature and immediately released 
from the mold. A representative picture of the RDTs at this stage 
is shown in Figure 2. The RDTs were cooled for an additional 30 
minutes, packaged into blister packs, and sealed with an adhesive 
label backing. 
STABILITY STUDY 
     For the stability study evaluation, the packaged RDTs were 
stored in a stability chamber maintained at 25°C ± 2ºC and 60% ± 
5% relative humidity (RH). Samples were withdrawn for analysis 
at 0, 2, 4, 9, 13, and 26 weeks. At each time point, twelve RDTs were 
taken out of the blister packs and subjected to visual inspection 
for color, shape, and physical defects. Their weights were also 
measured to monitor any potential moisture uptake. Six RDTs 
were then analyzed by the United States Pharmacopeia (USP) 
disintegration test, using a Varian VK 100 model (Cary, North 
Carolina) with water as the media.10 Three RDTs were analyzed by 
the stability-indicating HPLC method described below. 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
     The HPLC analysis was performed using a model LC-2010A sys-
tem with LC Solution software from Shimadzu Scientific Instru-
ments (Marlborough, Massachusetts). A Hypersil ODS-2 C18 col-
umn (150 × 4.6 mm, 5 µ) from Fisher Scientific (Cat 31605154630) 
was used and maintained at 30ºC. The mobile phase consisted of 
acetonitrile:water 45:55 (v/v), and the flow rate was 0.8 mL/min. 
The sample injection volume was 25 µL, and the ultraviolet detec-
tion was set at 207 nm. Under these HPLC conditions, the reten-
tion time of the drug was approximately 8.0 min. A representative 
HPLC chromatogram is shown in Figure 3. 
     For the potency and stability analysis, three RDTs from each 
time point were aggregated and crushed to a fine powder in a glass 
mortar and pestle. Three samples of about one-half tablet weight 
were weighed out and placed in to Class-A, 25-mL volumetric 
flasks. The flasks were brought to volume with the mobile phase, 
and the nominal DHEA concentration was about 0.2 mg/mL. The 
samples were shaken vigorously for the drug to fully dissolve. Ap-
proximately a 2-mL aliquot of each sample was withdrawn and fil-
tered through a PVDF 0.45-µm syringe filter into an HPLC vial for 
analysis. Each sample was analyzed by three replicate injections. 
The average DHEA RDT potency and percent label claims were 
calculated for each stability time point. The HPLC chromatograms 
were also carefully inspected for potential degradation products. 
     For calibration purpose, DHEA standard solutions were 
prepared at 0.12, 0.16, 0.20, 0.24, and 0.28 mg/mL. A five-point 
standard curve was generated on each analysis day. The curves 
were found to be linear over the concentration range of the 
standards with a regression coefficient (r) of 0.99 or better. The 
precision of the method was established by multiple injections of 
the mid-point standard (0.2 mg/mL) throughout each analysis day. 
The intra-day and inter-day coefficients of variation were within 
0.2% and 1.1%, respectively. Additionally, a blank RDT sample was 
prepared and analyzed on each analysis day to confirm that there 
was no interference from the RDT excipients. 
FORCED DEGRADATION STUDY
     In order to verify that the above HPLC method was stability indi-
cating, four DHEA solution samples at 0.2 mg/mL were prepared for 
a forced degradation study. Samples 1 and 2 were adjusted to pH 2 
and 12 with hydrochloric acid and sodium hydroxide, respectively. 
Samples 3 and 4 were each spiked with hydrogen peroxide for a final 
concentration of 3%. Samples 1 through 3 were incubated at 60ºC in 
a convection oven, and Sample 4 was kept on a windowsill (ambient 
room temperature) and exposed to direct sunlight. 
     All four samples were analyzed at initial time, 3 hours, 24 hours, 
72 hours, and 7 days using the HPLC method described above. No 
F I G U R E  3 .  A REPRESENTATIVE HIGH-PERFORMANCE LIQUID 
CHROMATOGRAM OF 0.2-MG/ML DEHYDROEPIANDROSTERONE.
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*Mean ± standard deviation (n=3)
T A B L E  2 .  HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY RESULTS OF 
DEHYDROEPIANDROSTERONE RAPID-DISSOLVING 
TABLETS STABILITY SAMPLES.
T I M E  ( W E E K )  %  L A B E L  C L A I M *
0 101.9 ± 0.32
2 101.0 ± 3.01
4 103.8 ± 2.95
9 100.2 ± 1.32
13 96.8 ± 0.33
26 99.4 ± 1.50
significant degradation was observed for Samples 1 or 2 after 
7 days. Sample 3 degraded by 62% after 3 hours, and Sample 4 
degraded by 91% after 7 days. The degradation peaks in both 
samples were well separated from that of the parent drug. Based 
on these results, the HPLC method was considered as stability 
indicating and deemed suitable for the proposed stability study 
of the DHEA RDTs.
RESULTS AND DISCUSSION
     The DHEA RDT formulation exhibited satisfactory chemical 
and physical stability during the compounding process. All 
resulting RDTs appeared as white and round tablets with no 
visible physical defects. The weight of twelve RDT samples 
averaged 637 mg (99.2% nominal value). The disintegrate time 
of the six RDTs ranged from 5 seconds to 40 seconds. The HPLC 
results showed that the initial potency was 101.9% of label claim. 
No new peaks were observed in the HPLC chromatograms, 
which suggested that DHEA, in this solid RDT formulation, was 
chemically stable against the 30-minute heating process at 100°C 
to 110°C employed during compounding. 
     Over 26 weeks (six months) of storage at 25°C/60% RH, the 
visual appearance remained mostly unchanged, and all stability 
samples retained their physical integrity with no obvious visual 
defects. No significant tablet weight gain was observed, suggest-
ing that there was minimal moisture uptake by the DHEA RDTs 
in the blister packs. The disintegration time also remained at 5 
seconds to 40 seconds for all stability samples. As shown in Table 
2, the HPLC results indicated that DHEA RDTs retained >95% of 
label claim throughout the six months of storage. No significant 
degradation products were detected by the stability-indicating 
HPLC method. 
     According to USP <795>, in the absence of established stabil-
ity data, the beyond-use date is recommended as 180 days (~ six 
months) for non-aqueous formulations.11 RDTs are a relatively 
new dosage form which may present unique stability challenges 
chemically and physically. For example, the compounding method 
for the formulation used in this study involves heating at 100°C to 
110°C, which is not typically used in compounding conventional 
solid dosage forms such as powders or capsules. Heating can lead 
to potential chemical instability of the drug and physical form 
change (e.g., crystalline to amorphous). By design, the RDT matrix 
is presumably more hygroscopic and porous than traditional com-
pressed tablets. The increased exposure to moisture and oxygen 
may also accelerate drug degradation during storage. With these 
considerations, it is prudent to conduct a stability study on a new 
drug RDT formulation and generate actual data to support the 
beyond-use date.
     The results from this pilot study confirmed that DHEA in the 
current RDT formulation is chemically stable against the heating 
step at 100°C to 110°C during compounding and remains stable 
over six months of storage at 25°C/60% RH. The additional data 
from visual inspection, weight check, and disintegration test also 
verified that the DHEA RDTs retained their physical integrity and 
rapid-dissolving property during this storage period.
     Several limitations of this study should be pointed out. This 
study evaluated only the RDT base formula and packaging materi-
als from one commercial supplier. The recommended storage 
condition was limited to one temperature/humidity. Finally, the 
disintegration test only confirmed that the tablet, not necessar-
ily the drug, was dissolving rapidly in an aqueous environment. 
Nevertheless, the results from this pilot study will be useful for the 
design of a comprehensive stability study in the future. 
CONCLUSION
     A pilot stability study was conducted on the 10-mg strength 
DHEA RDTs prepared using the RDT base formula and mold 
from PCCA. The DHEA RDTs was found to be stable chemically 
and physically during the compounding procedures and over six 
months of storage at 25°C and 60% RH. 
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